↓ Skip to main content

Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma

Overview of attention for article published in Cancer Cell International, January 2014
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
11 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma
Published in
Cancer Cell International, January 2014
DOI 10.1186/1475-2867-14-5
Pubmed ID
Authors

Zhiying Fu, Jun Zhu, Wen Zheng, Weiping Liu, Zhitao Ying, Yan Xie, Xiaopei Wang, Ningjing Lin, Meifeng Tu, Lingyan Ping, Lijuan Deng, Chen Zhang, Ning Ding, Yuqin Song

Abstract

Rituximab plus CHOP (R-CHOP) significantly improved the outcome of diffuse large B cell lymphoma (DLBCL), a common sub-type of non-Hodgkin lymphoma. But 40% - 50% of DLBCL patients cannot be cured by this regimen. Some clinical trials showed that bevacizumab might be useful in the treatment of DLBCL. This study evaluated the safety and efficacy of bevacizumab combined with the R-CHOP (A-R-CHOP) regimen in Chinese patients with previously untreated DLBCL.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 9%
United States 1 9%
Unknown 9 82%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 2 18%
Student > Master 2 18%
Other 2 18%
Researcher 2 18%
Student > Ph. D. Student 1 9%
Other 2 18%
Readers by discipline Count As %
Medicine and Dentistry 6 55%
Unspecified 2 18%
Nursing and Health Professions 1 9%
Psychology 1 9%
Pharmacology, Toxicology and Pharmaceutical Science 1 9%
Other 0 0%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 January 2014.
All research outputs
#3,029,230
of 4,508,238 outputs
Outputs from Cancer Cell International
#111
of 226 outputs
Outputs of similar age
#79,045
of 121,364 outputs
Outputs of similar age from Cancer Cell International
#9
of 24 outputs
Altmetric has tracked 4,508,238 research outputs across all sources so far. This one is in the 20th percentile – i.e., 20% of other outputs scored the same or lower than it.
So far Altmetric has tracked 226 research outputs from this source. They receive a mean Attention Score of 2.0. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 121,364 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.